Literature DB >> 26650878

Mixed chimerism evolution is associated with T regulatory type 1 (Tr1) cells in a β-thalassemic patient after haploidentical haematopoietic stem cell transplantation.

Marco Andreani1, Monica Emma Gianolini2, Manuela Testi1, MariaRosa Battarra1, Galluccio Tiziana1, Aldo Morrone1, Pietro Sodani3, Guido Lucarelli3, Maria-Grazia Roncarolo2,4, Silvia Gregori2.   

Abstract

In a cohort of β-Thalassemia (β-Thal) transplanted with haploidentical-HSCT we identified one transplanted patient characterized by persistent mixed chimerism (PMC) for several months after HSCT. In this unique β-Thal patient we assessed the donor engraftment overtime after transplantation, the potential loss of the non-shared HLA haplotype, and the presence of CD49b(+)LAG-3(+) T regulatory type 1 (Tr1) cells, previously demonstrated to be associated with PMC after HLA-related HSCT for β-Thal. The majority of the patient's erythrocytes were of donor origin, whereas T cells were initially mostly derived from the recipient, no HLA loss, but an increased frequency of circulating Tr1 cells were observed. For the first time, we showed that when the proportion of residual donor cells decreases, the frequency of CD49b(+)LAG-3(+) Tr1 cells declines, reaching the levels present in healthy subjects. These findings confirm previous results obtained in transplant related settings for β-Thal, and supported the central role of Tr1 cells in promoting and maintaining PMC after allo-HSCT.

Entities:  

Keywords:  Haploidentical HSCT; T regulatory type 1 (Tr1) cells; mixed chimerism

Mesh:

Year:  2015        PMID: 26650878      PMCID: PMC5063086          DOI: 10.1080/19381956.2015.1103423

Source DB:  PubMed          Journal:  Chimerism        ISSN: 1938-1964


  23 in total

Review 1.  Emerging concepts in haematopoietic cell transplantation.

Authors:  Hao Wei Li; Megan Sykes
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

Review 2.  Translational studies in hematopoietic cell transplantation: treatment of hematologic malignancies as a stepping stone to tolerance induction.

Authors:  Samuel Strober; Thomas R Spitzer; Robert Lowsky; Megan Sykes
Journal:  Semin Immunol       Date:  2011-06-25       Impact factor: 11.130

3.  Immunohematologic reconstitution in pediatric patients after T cell-depleted HLA-haploidentical stem cell transplantation for thalassemia.

Authors:  Antonella Isgrò; Marco Marziali; Pietro Sodani; Javid Gaziev; Buket Erer; Paola Polchi; Katia Paciaroni; Andrea Roveda; Gioia De Angelis; Cristiano Gallucci; Cecilia Alfieri; Maria Domenica Simone; Francesco Zinno; Giancarlo Isacchi; Gaspare Adorno; Alessandro Lanti; Wilma Leti; Fernando Aiuti; Daniela Fraboni; Marco Andreani; Guido Lucarelli
Journal:  Biol Blood Marrow Transplant       Date:  2010-06-25       Impact factor: 5.742

4.  Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells.

Authors:  Nicola Gagliani; Chiara F Magnani; Samuel Huber; Monica E Gianolini; Mauro Pala; Paula Licona-Limon; Binggege Guo; De'Broski R Herbert; Alessandro Bulfone; Filippo Trentini; Clelia Di Serio; Rosa Bacchetta; Marco Andreani; Leonie Brockmann; Silvia Gregori; Richard A Flavell; Maria-Grazia Roncarolo
Journal:  Nat Med       Date:  2013-04-28       Impact factor: 53.440

5.  Type 1 regulatory T cells are associated with persistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia.

Authors:  Giorgia Serafini; Marco Andreani; Manuela Testi; MariaRosa Battarra; Andrea Bontadini; Eika Biral; Katharina Fleischhauer; Sarah Marktel; Guido Lucarelli; Maria Grazia Roncarolo; Rosa Bacchetta
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

6.  HLA-mismatched renal transplantation without maintenance immunosuppression.

Authors:  Tatsuo Kawai; A Benedict Cosimi; Thomas R Spitzer; Nina Tolkoff-Rubin; Manikkam Suthanthiran; Susan L Saidman; Juanita Shaffer; Frederic I Preffer; Ruchuang Ding; Vijay Sharma; Jay A Fishman; Bimalangshu Dey; Dicken S C Ko; Martin Hertl; Nelson B Goes; Waichi Wong; Winfred W Williams; Robert B Colvin; Megan Sykes; David H Sachs
Journal:  N Engl J Med       Date:  2008-01-24       Impact factor: 91.245

7.  Long-term tolerance to kidney allografts after induced rejection of donor hematopoietic chimerism in a preclinical canine model.

Authors:  Scott S Graves; David W Mathes; George E Georges; Christian S Kuhr; Jeff Chang; Tiffany M Butts; Rainer Storb
Journal:  Transplantation       Date:  2012-09-27       Impact factor: 4.939

8.  Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease.

Authors:  Marco Andreani; Manuela Testi; Javid Gaziev; Rossella Condello; Andrea Bontadini; Pier Luigi Tazzari; Francesca Ricci; Lidia De Felice; Francesca Agostini; Daniela Fraboni; Giuliana Ferrari; Mariarosa Battarra; Maria Troiano; Pietro Sodani; Guido Lucarelli
Journal:  Haematologica       Date:  2010-10-07       Impact factor: 9.941

Review 9.  Clinical tolerance in allogeneic hematopoietic stem cell transplantation.

Authors:  Maria-Grazia Roncarolo; Silvia Gregori; Barbarella Lucarelli; Fabio Ciceri; Rosa Bacchetta
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

10.  Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells.

Authors:  Chiara F Magnani; Giada Alberigo; Rosa Bacchetta; Giorgia Serafini; Marco Andreani; Maria Grazia Roncarolo; Silvia Gregori
Journal:  Eur J Immunol       Date:  2011-05-13       Impact factor: 5.532

View more
  6 in total

Review 1.  Cure for thalassemia major - from allogeneic hematopoietic stem cell transplantation to gene therapy.

Authors:  Alok Srivastava; Ramachandran V Shaji
Journal:  Haematologica       Date:  2016-12-01       Impact factor: 9.941

2.  Long-term outcome of mixed chimerism after stem cell transplantation for thalassemia major conditioned with busulfan and cyclophosphamide.

Authors:  N A Fouzia; E S Edison; K M Lakshmi; A Korula; S R Velayudhan; P Balasubramanian; A Abraham; A Viswabandya; B George; V Mathews; A Srivastava
Journal:  Bone Marrow Transplant       Date:  2017-10-16       Impact factor: 5.483

3.  Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients.

Authors:  Pauline P Chen; Alma-Martina Cepika; Rajni Agarwal-Hashmi; Gopin Saini; Molly J Uyeda; David M Louis; Brandon Cieniewicz; Mansi Narula; Laura C Amaya Hernandez; Nicholas Harre; Liwen Xu; Benjamin Craig Thomas; Xuhuai Ji; Parveen Shiraz; Keri M Tate; Dana Margittai; Neehar Bhatia; Everett Meyer; Alice Bertaina; Mark M Davis; Rosa Bacchetta; Maria Grazia Roncarolo
Journal:  Sci Transl Med       Date:  2021-10-27       Impact factor: 19.319

4.  Regulatory T cells promote alloengraftment in a model of late-gestation in utero hematopoietic cell transplantation.

Authors:  John S Riley; Lauren E McClain; John D Stratigis; Barbara E Coons; Nicholas J Ahn; Haiying Li; Stavros P Loukogeorgakis; Camila G Fachin; Andre I B S Dias; Alan W Flake; William H Peranteau
Journal:  Blood Adv       Date:  2020-03-24

5.  Molecular and functional heterogeneity of IL-10-producing CD4+ T cells.

Authors:  Leonie Brockmann; Shiwa Soukou; Babett Steglich; Paulo Czarnewski; Lilan Zhao; Sandra Wende; Tanja Bedke; Can Ergen; Carolin Manthey; Theodora Agalioti; Maria Geffken; Oliver Seiz; Sara M Parigi; Chiara Sorini; Jens Geginat; Keishi Fujio; Thomas Jacobs; Thomas Roesch; Jacob R Izbicki; Ansgar W Lohse; Richard A Flavell; Christian Krebs; Jan-Ake Gustafsson; Per Antonson; Maria Grazia Roncarolo; Eduardo J Villablanca; Nicola Gagliani; Samuel Huber
Journal:  Nat Commun       Date:  2018-12-21       Impact factor: 14.919

Review 6.  The Yin and Yang of Type 1 Regulatory T Cells: From Discovery to Clinical Application.

Authors:  Ece Canan Sayitoglu; Robert Arthur Freeborn; Maria Grazia Roncarolo
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.